Literature DB >> 12414201

Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial.

Paulus Kirchhof1, Lars Eckardt, Peter Loh, Karoline Weber, Rudolf-Josef Fischer, Karl-Heinz Seidl, Dirk Böcker, Günter Breithardt, Wilhelm Haverkamp, Martin Borggrefe.   

Abstract

BACKGROUND: External cardioversion is a readily available treatment for persistent atrial fibrillation. Although anatomical and electrophysiological considerations suggest that an anterior-posterior electrode position should create a more homogeneous shock-field gradient throughout the atria than an anterior-lateral position, both electrode positions are equally recommended for external cardioversion in current guidelines. We undertook a randomised trial comparing the two positions with the endpoint of successful cardioversion.
METHODS: 108 consecutive patients (mean age 60 years [SD 16]) with persistent atrial fibrillation (median duration 5 months, range 0.1-120) underwent elective external cardioversion by a standardised step-up protocol with increasing shock strengths (50-360 J). Electrode positions were randomly assigned as anterior-lateral or anterior-posterior. If sinus rhythm was not achieved with 360 J energy, a single cross-over shock (360 J) was applied with the other electrode configuration. A planned interim analysis was done after these patients had been recruited; it was by intention to treat.
FINDINGS: Cardioversion was successful in a higher proportion of the anterior-posterior than the anterior-lateral group (50 of 52 [96%] vs 44 of 56 [78%], difference 23.7% (95% CI 9.1-37.8, p=0.009). Cross-over from the anterior-lateral to the anterior-posterior electrode position was successful in eight of 12 patients, whereas cross-over in the other direction was not successful (two patients). After cross-over, cardioversion was successful in 102 of 108 randomised patients (94%).
INTERPRETATION: An anterior-posterior electrode position is more effective than the anterior-lateral position for external cardioversion of persistent atrial fibrillation. These results should be considered in clinical practice, for the design of defibrillation electrode pads, and when guidelines for cardioversion of atrial fibrillation are updated.

Entities:  

Mesh:

Year:  2002        PMID: 12414201     DOI: 10.1016/s0140-6736(02)11315-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  Importance of using biphasic shock waveforms for cardioversion from atrial fibrillation: an unresolved issue.

Authors:  J M Morgan
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 2.  Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion.

Authors:  A A J Adgey; S J Walsh
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

3.  Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease.

Authors:  Mark A Peterman; Hassan Farooq; William C Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-04

Review 4.  [Electrical and pharmacological strategies for early cardioversion of atrial fibrillation].

Authors:  M Linhart; T Lewalter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 5.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

6.  [Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

Authors:  P Kirchhof; A Goette; G Hindricks; S Hohnloser; K-H Kuck; T Meinertz; U Ravens; G Steinbeck; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

7.  Cardioversion: past, present, and future.

Authors:  Ivan Cakulev; Igor R Efimov; Albert L Waldo
Journal:  Circulation       Date:  2009-10-20       Impact factor: 29.690

Review 8.  [Anticoagulation with atrial fibrillation].

Authors:  S Zellerhoff; A Goette; P Kirchhof
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

9.  Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.

Authors:  Fikret Er; Orhan Aslan; Evren Caglayan; Natig Gassanov; Amir M Nia; Erland Erdmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2010-02-24       Impact factor: 5.460

Review 10.  [Current treatment of tachycardia].

Authors:  J Tebbenjohanns; K Rühmkorf
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.